QUINCE THERAPEUTICS INC (QNCX) Stock Price, Quote, News and Overview
NASDAQ:QNCX - Nasdaq - US22053A1079 - Common Stock - Currency: USD
QNCX Quote, Performance and Key Statistics
1.04
0 (0%)
The current stock price of QNCX is 1.04 USD. In the past month the price decreased by -3.7%. In the past year, price increased by 25.3%.
QNCX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.12 | 328.74B | ||
| AMGN | AMGEN INC | 13.88 | 154.96B | ||
| GILD | GILEAD SCIENCES INC | 14.22 | 136.93B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.52B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.06 | 52.94B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.71B | ||
| ARGX | ARGENX SE - ADR | 99.7 | 35.00B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.29 | 26.55B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.03B | ||
| NTRA | NATERA INC | N/A | 21.54B | ||
| BIIB | BIOGEN INC | 8.2 | 19.02B | ||
| UTHR | UNITED THERAPEUTICS CORP | 12.72 | 14.38B |
Related stock screener links
About QNCX
Company Profile
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient’s biology for the treatment of rare diseases. The company is headquartered in South San Francisco, California and currently employs 36 full-time employees. The company went IPO on 2019-05-09. The firm is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.
Company Info
QUINCE THERAPEUTICS INC
601 Gateway Boulevard, Suite 1250
South San Francisco CALIFORNIA US
Employees: 36
Phone: 14159105717
QUINCE THERAPEUTICS INC / QNCX FAQ
What is the stock price of QUINCE THERAPEUTICS INC today?
The current stock price of QNCX is 1.04 USD.
What is the ticker symbol for QUINCE THERAPEUTICS INC stock?
The exchange symbol of QUINCE THERAPEUTICS INC is QNCX and it is listed on the Nasdaq exchange.
On which exchange is QNCX stock listed?
QNCX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for QUINCE THERAPEUTICS INC stock?
10 analysts have analysed QNCX and the average price target is 7.4 USD. This implies a price increase of 611.06% is expected in the next year compared to the current price of 1.04. Check the QUINCE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is QUINCE THERAPEUTICS INC worth?
QUINCE THERAPEUTICS INC (QNCX) has a market capitalization of 47.29M USD. This makes QNCX a Nano Cap stock.
How many employees does QUINCE THERAPEUTICS INC have?
QUINCE THERAPEUTICS INC (QNCX) currently has 36 employees.
What are the support and resistance levels for QUINCE THERAPEUTICS INC (QNCX) stock?
QUINCE THERAPEUTICS INC (QNCX) has a support level at 1.03 and a resistance level at 1.07. Check the full technical report for a detailed analysis of QNCX support and resistance levels.
Should I buy QUINCE THERAPEUTICS INC (QNCX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of QNCX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of QNCX, evaluating the profitability, health, valuation and growth aspects
- QUINCE THERAPEUTICS INC (QNCX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- QUINCE THERAPEUTICS INC (QNCX) Sales and EPS estimates to see what analysts future expectations are.
- QUINCE THERAPEUTICS INC (QNCX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- QUINCE THERAPEUTICS INC (QNCX) Insider and Institutional Ownership to learn about the owners and their transactions.
- QUINCE THERAPEUTICS INC (QNCX) Stock Chart to make your own analysis
- QUINCE THERAPEUTICS INC (QNCX) Latest news and press-releases to stay up to date.
Does QUINCE THERAPEUTICS INC (QNCX) stock pay dividends?
QNCX does not pay a dividend.
When does QUINCE THERAPEUTICS INC (QNCX) report earnings?
QUINCE THERAPEUTICS INC (QNCX) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of QUINCE THERAPEUTICS INC (QNCX)?
QUINCE THERAPEUTICS INC (QNCX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.4).
What is the Short Interest ratio of QUINCE THERAPEUTICS INC (QNCX) stock?
The outstanding short interest for QUINCE THERAPEUTICS INC (QNCX) is 2.77% of its float. Check the ownership tab for more information on the QNCX short interest.
QNCX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to QNCX. When comparing the yearly performance of all stocks, QNCX turns out to be only a medium performer in the overall market: it outperformed 43.7% of all stocks.
QNCX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to QNCX. QNCX has a bad profitability rating. Also its financial health evaluation is rather negative.
QNCX Financial Highlights
Over the last trailing twelve months QNCX reported a non-GAAP Earnings per Share(EPS) of -1.4. The EPS decreased by -82.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.69% | ||
| ROE | -326.73% | ||
| Debt/Equity | 0.82 |
QNCX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to QNCX. The Buy consensus is the average rating of analysts ratings from 10 analysts.